Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Update: FDA Wants To Automatically Extend Complex Application Reviews

Executive Summary

FDA wants industry to agree to a set of reasons that would automatically trigger a longer application review as part of the negotiations on reauthorizing the Prescription Drug User Fee Act.

You may also be interested in...



NDA Data Standardization Efforts Emerging Along Public, Private Fronts

FDA appears to be using a multi-front strategy for designing and implementing plans to standardize electronic data formats and application filings.

NDA Data Standardization Efforts Emerging Along Public, Private Fronts

FDA appears to be using a multi-front strategy for designing and implementing plans to standardize electronic data formats and application filings.

PDUFA V: FDA Could Offer Non-Binding Advice, If It’s Binding

FDA is interested in giving non-binding advice to drug sponsors under PDUFA V, as long as it is binding, officials told industry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel